BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38339343)

  • 101. Recent advances in diagnosis and therapy in systemic mastocytosis.
    Lee HJ
    Blood Res; 2023 Apr; 58(S1):96-108. PubMed ID: 37105564
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant.
    Sriskandarajah P; McLornan DP; Oni C; Wilson AJ; Woodley C; Ciesielska M; Raj K; Dillon R; Ethell M; Chacko J; Orchard K; Radia DH
    Curr Res Transl Med; 2023; 71(3):103398. PubMed ID: 37331225
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia.
    Sandow L; Heinrich M
    Leuk Res Rep; 2023; 19():100371. PubMed ID: 37305181
    [TBL] [Abstract][Full Text] [Related]  

  • 104. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.
    Mancini M; Monaldi C; De Santis S; Papayannidis C; Rondoni M; Sartor C; Bruno S; Pagano L; Criscuolo M; Zanotti R; Bonifacio M; Tosi P; Arock M; Valent P; Cavo M; Soverini S
    Biomark Res; 2023 Mar; 11(1):29. PubMed ID: 36894973
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation.
    Chow S; Lee S; Lin A; Craddock KJ; Smith AC; Tsui H
    Br J Haematol; 2024 May; ():. PubMed ID: 38702998
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
    McLornan DP; Czerw T; Damaj G; Ethell M; Gurnari C; Hernández-Boluda JC; Polverelli N; Schwaab J; Sockel K; Raffaella G; Onida F; Sánchez-Ortega I; Battipaglia G; Elena C; Gotlib J; Reiter A; Rossignol J; Ustun C; Valent P; Yakoub-Agha I; Radia DH
    Leukemia; 2024 Apr; 38(4):699-711. PubMed ID: 38472477
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in
    Naumann N; Rudelius M; Lübke J; Christen D; Bresser J; Sotlar K; Metzgeroth G; Fabarius A; Hofmann WK; Panse J; Horny HP; Cross NCP; Reiter A; Schwaab J
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339343
    [TBL] [Abstract][Full Text] [Related]  

  • 109. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Response and progression on midostaurin in advanced systemic mastocytosis:
    Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
    Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
    Naumann N; Lübke J; Shomali W; Reiter L; Horny HP; Jawhar M; Dangelo V; Fabarius A; Metzgeroth G; Kreil S; Sotlar K; Oni C; Harrison C; Hofmann WK; Cross NCP; Valent P; Radia D; Gotlib J; Reiter A; Schwaab J
    Br J Haematol; 2021 Jul; 194(2):344-354. PubMed ID: 34060083
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
    Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
    Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
    [TBL] [Abstract][Full Text] [Related]  

  • 113. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
    Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
    Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.
    Kennedy VE; Perkins C; Reiter A; Jawhar M; Lübke J; Kluin-Nelemans HC; Shomali W; Langford C; Abuel J; Hermine O; Niedoszytko M; Gorska A; Mital A; Bonadonna P; Zanotti R; Tanasi I; Mattsson M; Hagglund H; Triggiani M; Yavuz AS; Panse J; Christen D; Heizmann M; Shoumariyeh K; Müller S; Elena C; Malcovati L; Fiorelli N; Wortmann F; Vucinic V; Brockow K; Fokoloros C; Papageorgiou SG; Breynaert C; Bullens D; Doubek M; Ilerhaus A; Angelova-Fischer I; Solomianyi O; Várkonyi J; Sabato V; Rüfer A; Schug TD; Hermans MAW; Fortina AB; Caroppo F; Bumbea H; Gulen T; Hartmann K; Elberink HO; Schwaab J; Arock M; Valent P; Sperr WR; Gotlib J
    Blood Adv; 2023 May; 7(9):1713-1724. PubMed ID: 36094848
    [TBL] [Abstract][Full Text] [Related]  

  • 115. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
    Arber DA; Orazi A; Hasserjian RP; Borowitz MJ; Calvo KR; Kvasnicka HM; Wang SA; Bagg A; Barbui T; Branford S; Bueso-Ramos CE; Cortes JE; Dal Cin P; DiNardo CD; Dombret H; Duncavage EJ; Ebert BL; Estey EH; Facchetti F; Foucar K; Gangat N; Gianelli U; Godley LA; Gökbuget N; Gotlib J; Hellström-Lindberg E; Hobbs GS; Hoffman R; Jabbour EJ; Kiladjian JJ; Larson RA; Le Beau MM; Loh ML; Löwenberg B; Macintyre E; Malcovati L; Mullighan CG; Niemeyer C; Odenike OM; Ogawa S; Orfao A; Papaemmanuil E; Passamonti F; Porkka K; Pui CH; Radich JP; Reiter A; Rozman M; Rudelius M; Savona MR; Schiffer CA; Schmitt-Graeff A; Shimamura A; Sierra J; Stock WA; Stone RM; Tallman MS; Thiele J; Tien HF; Tzankov A; Vannucchi AM; Vyas P; Wei AH; Weinberg OK; Wierzbowska A; Cazzola M; Döhner H; Tefferi A
    Blood; 2022 Sep; 140(11):1200-1228. PubMed ID: 35767897
    [TBL] [Abstract][Full Text] [Related]  

  • 116. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
    Khoury JD; Solary E; Abla O; Akkari Y; Alaggio R; Apperley JF; Bejar R; Berti E; Busque L; Chan JKC; Chen W; Chen X; Chng WJ; Choi JK; Colmenero I; Coupland SE; Cross NCP; De Jong D; Elghetany MT; Takahashi E; Emile JF; Ferry J; Fogelstrand L; Fontenay M; Germing U; Gujral S; Haferlach T; Harrison C; Hodge JC; Hu S; Jansen JH; Kanagal-Shamanna R; Kantarjian HM; Kratz CP; Li XQ; Lim MS; Loeb K; Loghavi S; Marcogliese A; Meshinchi S; Michaels P; Naresh KN; Natkunam Y; Nejati R; Ott G; Padron E; Patel KP; Patkar N; Picarsic J; Platzbecker U; Roberts I; Schuh A; Sewell W; Siebert R; Tembhare P; Tyner J; Verstovsek S; Wang W; Wood B; Xiao W; Yeung C; Hochhaus A
    Leukemia; 2022 Jul; 36(7):1703-1719. PubMed ID: 35732831
    [TBL] [Abstract][Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.